Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Pipeline Review, H1 2017

Publisher Name :
Date: 13-Jun-2017
No. of pages: 49

Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Pipeline Review, H1 2017

Summary

According to the recently published report 'Integrin Beta 1 - Pipeline Review, H1 2017'; Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) pipeline Target constitutes close to 16 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes.

Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Integrin beta-1 also known as CD29 is a protein encoded by the ITGB1 gene. It is involved in up-regulation of the activity of kinases such as PKC via binding to KRT1. It plays a mechanistic adhesive role during telophase. Integrin alpha-3/beta-1 provides a docking site for FAP at invadopodia plasma membranes in a collagen-dependent manner and participates in the adhesion, formation of invadopodia and matrix degradation processes, promoting cell invasion.

The report 'Integrin Beta 1 - Pipeline Review, H1 2017' outlays comprehensive information on the Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviewsalso reviews key players involved in Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 8 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Musculoskeletal Disorders, Genetic Disorders, Ophthalmology, Cardiovascular, Dermatology, Immunology, Oncology and Respiratory which include indications Muscular Dystrophy, Duchenne Muscular Dystrophy, Wet (Neovascular / Exudative) Macular Degeneration, Arterial Thrombosis, Breast Cancer, Cardiovascular Disease, Prostate Cancer, Pulmonary Fibrosis, Rheumatoid Arthritis and Scar.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1)

- The report reviews Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics and enlists all their major and minor projects

- The report assesses Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for

- Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Pipeline Review, H1 2017

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Overview
Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Companies Involved in Therapeutics Development
Clanotech AB
Strykagen Corp
Valeant Pharmaceuticals International Inc
Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Drug Profiles
AXT-108 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-16Y - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLT-28643 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAL-021 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Integrin alpha 2 beta 1 for Arterial Thrombosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Integrin Alpha V and Beta 1 for Cardiovascular Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stryka-232 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stryka-234 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stryka-425 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stryka-516 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stryka-516s - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stryka-533 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stryka-969 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stryka-978 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
StrykaPro-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Antagonize Alpha5Beta1 Integrin for Breast and Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Dormant Products
Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Discontinued Products
Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Product Development Milestones
Featured News & Press Releases
Jun 15, 2015: Clanotech's lead compound in development, CLT-28643, has recently been granted a European Patent by the European Patent Office
May 12, 2015: Clanotech to present CLT-28643 in the treatment of eye disease at BioTrinity 2015 on 13 May 2015
Mar 27, 2015: Clanotech granted Orphan Drug Designation by the U.S. FDA
Oct 20, 2014: Clanotech receives orphan drug designation in the EU
Dec 23, 2013: Santarus Initiates Phase IIa Study with SAN-300 in Patients with Active Rheumatoid Arthritis
Oct 25, 2013: Santarus Announces Presentation of SAN-300 Phase I Data at 2013 American College of Rheumatology Annual Meeting
Mar 10, 2011: Santarus Initiates Phase I Clinical Study With SAN-300
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Indication, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products under Investigation by Universities/Institutes, H1 2017
Products under Investigation by Universities/Institutes, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Pipeline by Clanotech AB, H1 2017
Pipeline by Strykagen Corp, H1 2017
Pipeline by Valeant Pharmaceuticals International Inc, H1 2017
Dormant Products, H1 2017
Dormant Products, H1 2017 (Contd..1), H1 2017
Dormant Products, H1 2017 (Contd..2), H1 2017
Discontinued Products, H1 2017

List of Figures
Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Top 10 Indications, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
  • Asia Pacific Crispr Market Forecast 2019-2027
    Published: 10-Dec-2018        Price: US 1250 Onwards        Pages: 91
    KEY FINDINGS The revenue generated by the Asia-Pacific CRISPR market is expected to multiply over the forecast period of 2019-2027, due to an expected CAGR of 33.84%. CRISPR majorly finds its applications in industries like agriculture and animal breeding for this region. MARKET INSIGHTS China, Japan, and India are some of the major markets contributing to the Asia-Pacific CRISPR market. The Japanese CRISPR market contributed the highest revenue share in 2018, but it......
  • Europe Crispr Market Forecast 2019-2027
    Published: 10-Dec-2018        Price: US 1250 Onwards        Pages: 99
    KEY FINDINGS Clustered regularly interspaced short palindrome repeats (CRISPR) are fragments of prokaryotic DNA containing short redundancies of base sequences. The European market for CRISPR is anticipated to evolve with 30.98% CAGR over the forecast period of 2019-2027. MARKET INSIGHTS U.K market dominated the Europe CRISPR market in 2018 and is expected to continue its dominance throughout the forecast period. Growing stem cell research in the region is significan......
  • North America Crispr Market Forecast 2019-2027
    Published: 10-Dec-2018        Price: US 1250 Onwards        Pages: 102
    KEY FINDINGS Over the forecast period of 2019-2027, the North America CRISPR market is projected to witness a CAGR of 31.97% accounting for the highest revenue share, as compared to other regional markets. MARKET INSIGHTS Pharmaceutical industries are the key end-users of the CRISPRs in this region. Also, the growing market for stem cell therapy is considerably fueling the demand for the CRISPR market. Increasing grant for orphan drug status for stem cell therapeutic......
  • Global Crispr Market Forecast 2019-2027
    Published: 10-Dec-2018        Price: US 2500 Onwards        Pages: 158
    KEY FINDINGS The Global CRISPR market is expected to witness a boost of 32.04% CAGR over the forecast period of 2019-2027. Factors like increasing demand of the technology for drug discovery, late pregnancies leading to birth disorders and growing investments for path-breaking research technology are fueling the market growth. MARKET INSIGHTS The global CRISPR market is segmented on the basis of products, applications, end-users. The product segment includes plasmids......
  • Global and Chinese Organs-on-chips Industry, 2018 Market Research Report
    Published: 10-Dec-2018        Price: US 3000 Onwards        Pages: 137
    The 'Global and Chinese Organs-on-chips Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global Organs-on-chips industry with a focus on the Chinese market. The report provides key statistics on the market status of the Organs-on-chips manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of the industry including its defin......
  • Global and Chinese Bioanalytical Testing Services Industry, 2018 Market Research Report
    Published: 10-Dec-2018        Price: US 3000 Onwards        Pages: 137
    The 'Global and Chinese Bioanalytical Testing Services Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global Bioanalytical Testing Services industry with a focus on the Chinese market. The report provides key statistics on the market status of the Bioanalytical Testing Services manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic......
  • Global Cell Therapy Market Research Report 2012-2023
    Published: 09-Dec-2018        Price: US 5060 Onwards        Pages: 127
    Summary The global Cell Therapy market will reach xxx Million USD in 2017 with CAGR xx% 2018-2023. The objective of report is to define, segment, and project the market on the basis of product type, application, and region, and to describe the content about the factors influencing market dynamics, policy, economic, technology and market entry etc. Based on products type, the report describes major products type share of regional market. Products mentioned as follows......
  • Global and Chinese Biobanking Industry, 2018 Market Research Report
    Published: 09-Dec-2018        Price: US 3000 Onwards        Pages: 140
    The 'Global and Chinese Biobanking Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global Biobanking industry with a focus on the Chinese market. The report provides key statistics on the market status of the Biobanking manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of the industry including its definition, applicat......
  • Global and Chinese Medical Swab Industry, 2018 Market Research Report
    Published: 08-Dec-2018        Price: US 3000 Onwards        Pages: 150
    The 'Global and Chinese Medical Swab Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global Medical Swab industry with a focus on the Chinese market. The report provides key statistics on the market status of the Medical Swab manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of the industry including its definition, ap......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs